Buy Montelukast Uk
Most people take montelukast once a day in the evening to prevent symptoms of asthma or allergies. However, if exercise makes your asthma worse, your doctor might tell you to take montelukast 2 hours before you exercise.
buy montelukast uk
There is not much information about montelukast in breastfeeding, but the information shows that montelukast passes into breast milk in tiny amounts. It has not been known to cause any side effects in breastfed babies.
It's usually safe to take everyday painkillers with montelukast. However, do not take non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen if they've ever made your asthma symptoms worse.
There's not enough information to say that complementary medicines and herbal remedies are safe to take with montelukast. They're not tested in the same way as pharmacy and prescription medicines. They're generally not tested for the effect they have on other medicines.
It has been known for some time that neuropsychiatric reactions may occur in association with montelukast treatment, and these reactions are listed as possible side effects in the product information. A recent EU review confirmed the known risks of neuropsychiatric reactions and found that the magnitude of risk was unchanged. However, the review identified some cases in which there had been a delay in neuropsychiatric reactions being recognised as a possible adverse drug reaction.
A range of neuropsychiatric reactions has been reported in association with montelukast. Among these are: sleep disturbances, depression and agitation (may affect up to 1 in 100 people taking montelukast); disturbances of attention or memory (up to 1 in 1,000 people); and very rarely, hallucinations and suicidal behaviour (up to 1 in 10,000 people). See the Summary of Product Characteristics and the Patient Information Leaflet for full details.
In the UK, between 2014 and 2018, MHRA received 219 reports of suspected adverse neuropsychiatric reactions to the Yellow Card Scheme, during which time there were approximately 14 million prescriptions of montelukast. Since montelukast was first marketed in the UK, we have received 639 reports of suspected adverse neuropsychiatric reactions.
In the UK, the most frequently reported suspected neuropsychiatric reactions associated with montelukast have been nightmares/night terrors, depression, insomnia, aggression, anxiety and abnormal behaviour or changes in behaviour. These events were reported in all age groups. However, nightmare/night terrors, aggression, and behaviour changes are more frequently reported in the paediatric population.
The product information is also being updated to include stuttering and obsessive-compulsive symptoms as very rare (thought to affect fewer than 1 in 10,000 patients) potential neuropsychiatric adverse events with montelukast.
Most people with asthma do not need montelukast, but it can be a useful add-on treatment to take alongside your usual preventer inhaler. Montelukast is not a steroid - it works in a different way to reduce inflammation.
The therapeutic effect of Singulair on parameters of asthma control occurs within one day. Singulair may be taken with or without food. Patients should be advised to continue taking Singulair even if their asthma is under control, as well as during periods of worsening asthma. Singulair should not be used concomitantly with other products containing the same active ingredient, montelukast.
Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled β-agonist should be used. Patients should seek their doctors' advice as soon as possible if they need more inhalations of short-acting β-agonists than usual.
In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.
Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products:
The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.